Method
Level · gp.fundamentals.debt_to_revenue
Raw value 100.89% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAkebia Therapeutics, Inc.'s latest supported as-filed period reports revenue of $49.1M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 100.89% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.20% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 7.18% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -21.36% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 26.50% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 78.78% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +13.3% from the comparable as-filed period.
Debt changed +5.3% from the comparable as-filed period. The change ranks at the 20th percentile of 5 prior comparable changes.
Inventory changed -22.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
AKBA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001591467-26-000004SEC ↗10-QAug 5, 2026Period Jun 30, 20260001517022-26-000051SEC ↗8-KAug 5, 2026Period Aug 5, 20260001517022-26-000050SEC ↗4Jul 1, 2026Period Jun 29, 20260001762507-26-000004SEC ↗8-KJun 30, 2026Period Jun 30, 20260001517022-26-000047SEC ↗4Jun 22, 2026Period Jun 17, 20260001808317-26-000001SEC ↗4Jun 22, 2026Period Jun 17, 20260001609480-26-000003SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value -12.88% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 28.62% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 6.57% · OPTIONAL
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Net income changed -3706.5% from the comparable as-filed period.
Operating income changed -144.9% from the comparable as-filed period.
Operating margin changed -3543 basis points from the comparable as-filed period.
Research & development changed +27.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001244159-26-000001